Nasdaq:US$13.65 (-0.24) | HKEX:HK$21.10 (-0.50) | AIM:£2.23 (-0.06)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.